TEAM (AT) WORK: EL.EN. and ASA united for technological development

09 December 2024 - Corporate -

Research and Development are the pillars on which all the companies of the El.En. Group base their growth: technological innovation, continuous training and know-how sharing are the key words that unite them. ASA also embraces these principles and, in the context of its expansion strategy, shares with El.En. a common vision that not only promotes collaboration and mutual fusion but stimulates interaction between resources to give shape to structured projects.

An example is the recent meeting held at ASA between the front line of R&D of the Florentine group and that of the Vicenza-based company: the two teams in fact held an all-around mutual discussion, sharing updates, development ideas and technological trajectories. The objective is clear: to define new plans and methods that are functional to maintaining their competitive positions on the market and, at the same time, to define other penetration channels by optimising the resources available.

The precedent: Hilterapia^®

However, this is not the first case of synergic work between the parent company and ASA, as is confirmed by the development of one of its leading therapies: Hilterapia^®. This therapeutic solution is in fact the result of the intuition of Prof Masotti, founding partner of El.En., later confirmed by Research, which gave rise to the patent underlying the Nd:YAG laser technology, brought to the market, spread through the medical field and subsequently disseminated throughout the world thanks to ASA and its devices, today HIRO and HIRO TT.

The key role of cooperation between the two entities is highlighted by Eng. Damiano Guidolin, General Manager of ASA:

Testo a Destra

Immagine 30%/Testo 60%

“The fusion between the talents of ASA and El.En. and the mutual transfer of skills are the basis of a desire for expansion that goes beyond the here and now and sets medium-long term goals. The prospects that are opening up allow glimpsing extremely interesting scenarios for the development of new devices, new and innovative therapeutic applications and new generation technologies applied to the respective areas of expertise”.

A similar assessment is given by Dr Marco Tagliaferri, Director of the Research and Development Department of the Medical Division of El.En. who comments

Testo a Sinistra

Immagine 30%/Testo 60%

Dott. Marco Tagliaferri, Direttore del Dipartimento di Ricerca e Sviluppo della Divisione Medicale di El.En.

“It is with great pleasure that we met the ASA Research and Development Team to assess together how to best exploit the skills relating to laser technology available in El.En. in order to more effectively promote innovation in the very interesting clinical applications of ASA. The meeting focused on two strategic projects, respectively in the short and medium term, which will be addressed during 2025. The ASA Team has reached a sufficient level of expertise and experience to independently manage the development of new systems and the related medical certifications: I believe that currently the most effective collaboration can be developed by means of sharing the laser technology available in El.En. which we are happy to make available in order to allow ASA to maintain the dominant position it has gained in recent years with Hilterapia^®”.